Stem Cell Clinic

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

By Global News Feed

SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.

Go here to see the original:
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

By Global News Feed

HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the closing of its previously announced public offering consisting of 1,555,555 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 1,555,555 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrants in lieu thereof) and accompanying common warrant of $4.50. The closing occurred on January 30, 2024.

Read the rest here:
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global…

By Global News Feed

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Read the original:
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global...

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

By Global News Feed

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of idiopathic inflammatory myopathies (IIM, or myositis). CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells. Four RESET™ (REstoring SElf-Tolerance) Phase 1/2 trials are advancing for the evaluation of CABA-201 across multiple autoimmune conditions, including the Phase 1/2 RESET-Myositis™ trial.

See the original post:
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

By Global News Feed

NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on Wednesday, February 7 at 10:30 a.m. ET in New York.

Here is the original post:
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

By Global News Feed

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -

See the rest here:
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

→←